AnaptysBio abandons eczema drug after trial failures; shares nosedive

Biotechnology company AnaptysBio, Inc., specializing in innovative autoimmune disease therapies, announced it will halt development of its atopic dermatitis treatment, ANB032, after the drug failed to meet efficacy targets in a crucial Phase 2b trial. The disappointing clinical trial results led to a sharp decline in AnaptysBio shares, which plummeted over 39% to $14 in premarket trading on Wednesday.

The investigational eczema drug failure was highlighted during the ARISE-AD study, which assessed ANB032’s potential as a monotherapy for moderate-to-severe atopic dermatitis, a chronic skin condition. Despite being well tolerated and showing no safety signals, the drug did not achieve its primary or secondary endpoints, including significant improvements in the Eczema Area Severity Index (EASI) and itch severity compared to placebo.

Clinical Outcomes and Observations

The ARISE-AD trial enrolled 201 patients from the U.S., Canada, Europe, Australia, and New Zealand. Participants were either biologic-naïve or had prior experience with biologic treatments like dupilumab. The study’s primary goal was to evaluate whether ANB032 could deliver a 75% improvement in EASI scores, a critical marker for atopic dermatitis treatment success. However, the failed trial endpoints revealed the drug’s inability to meet expectations, with higher-than-normal placebo response rates further complicating its performance analysis.

“While ANB032 was safe and well tolerated, we’re disappointed by these efficacy results and will discontinue further investment in this asset,” said Daniel Faga, Chief Executive Officer of AnaptysBio. “Our resources will now focus on advancing other autoimmune disease therapies in our pipeline.”

Strategic Shift Toward Promising Drug Candidates

The eczema drug failure has prompted AnaptysBio to pivot its attention to more promising clinical programs. The company’s lead asset, rosnilimab, a PD-1+ T cell depleter, is currently in a Phase 2b trial for rheumatoid arthritis and a Phase 2 trial for ulcerative colitis. The top-line Phase 2b clinical trial results for rosnilimab in rheumatoid arthritis are expected in February 2025, with additional data for ulcerative colitis anticipated in early 2026.

In addition to rosnilimab, AnaptysBio’s pipeline includes ANB033, an anti-CD122 antagonist, and ANB101, a BDCA2 modulator, which are advancing through early-stage trials. These autoimmune disease therapies reflect the company’s strategic focus on addressing unmet needs in inflammatory conditions.

Financially, AnaptysBio remains stable, reporting $415 million in cash reserves as of year-end 2024. This robust financial position supports its operations through 2027, excluding potential milestone payments and royalties from collaborations with partners such as GlaxoSmithKline.

Acknowledgment of Trial Participants

The failed trial endpoints underscore the challenges of developing effective therapies for atopic dermatitis. Paul Lizzul, Chief Medical Officer at AnaptysBio, expressed gratitude to the clinicians and patients who participated in the ARISE-AD trial. “We sincerely appreciate the dedication of everyone involved in advancing research for this debilitating chronic disease,” he said.

Atopic dermatitis, often referred to as eczema, affects millions worldwide and presents a significant need for effective treatments. The ARISE-AD study aimed to explore new avenues for atopic dermatitis treatment, but the disappointing clinical trial results have shifted focus to other areas of research.

Investor and Market Sentiment

The failure of ANB032 represents a setback for biotechnology company AnaptysBio, which had high hopes for the drug’s potential. Market reaction has been swift, with the sharp drop in share value reflecting investor skepticism about the company’s ability to recover from this loss. However, the focus on autoimmune disease therapies, coupled with a strong financial runway, positions AnaptysBio to potentially rebound with future successes.